TNGX - Tango Therapeutics Inc

TNGX - Tango Therapeutics Inc

https://www.tangotx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

GlobeNewswire • 2 weeks, 6 days ago • score: -0.11

BOSTON, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on ...

Tango Therapeutics, Inc. ( TNGX ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.21

Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - Tango Therapeutics ( NASDAQ:TNGX )

Benzinga • 1 month, 3 weeks ago • score: -0.10

BOSTON, July 22, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. TNGX, today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$10.85

52W Low

$1.03

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.65

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.91

EV/Revenue (<3 favorable)

25.78

P/S (TTM) (<3 favorable)

31.78

P/B (<3 favorable)

5.72

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

12.26%

Institutions (25–75% balanced)

110.16%

Shares Outstanding

111,260,000

Float

36,674,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

24,296,000

Gross Profit (TTM)

-112,152,000

EPS (TTM)

-1.32

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-12.88%

ROE (TTM) (>15% strong)

-0.76%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.84

Momentum

Bearish momentum

Value

0.0368

Previous

0.0650

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025